search
Back to results

A Compassionate Use (CU) Program of Odronextamab

Primary Purpose

Relapsed or Refractory (R/R) Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Non-Hodgkin Lymphoma (NHL)

Status
Available
Phase
Locations
Study Type
Expanded Access
Intervention
Odronextamab
Sponsored by
Regeneron Pharmaceuticals
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an expanded access trial for Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All Sexes

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    November 8, 2022
    Last Updated
    July 7, 2023
    Sponsor
    Regeneron Pharmaceuticals
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05619367
    Brief Title
    A Compassionate Use (CU) Program of Odronextamab
    Study Type
    Expanded Access

    2. Study Status

    Record Verification Date
    July 2023
    Overall Recruitment Status
    Available
    Study Start Date
    undefined (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Regeneron Pharmaceuticals

    4. Oversight

    5. Study Description

    Brief Summary
    Provide compassionate use of odronextamab

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Relapsed or Refractory (R/R) Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Non-Hodgkin Lymphoma (NHL), High-Grade B-Cell Lymphoma (HGBCL)

    7. Study Design

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    Odronextamab
    Other Intervention Name(s)
    REGN1979

    10. Eligibility

    Sex
    All
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Requests for compassionate use must be initiated by a treating physician Physicians should contact
    Phone
    844-734-6643
    Email
    CompassionateUseRequests@regeneron.com

    12. IPD Sharing Statement

    Learn more about this trial

    A Compassionate Use (CU) Program of Odronextamab

    We'll reach out to this number within 24 hrs